Leslie M Swanson, Trevor de Sibour, Kelley DuBuc, Deirdre A Conroy, Greta B Raglan, Kate Lorang, Jennifer Zollars, Shelley Hershner, J Todd Arnedt, Helen J Burgess
STUDY OBJECTIVES: The purpose of the present study was to preliminarily evaluate whether knowing the dim light melatonin onset (DLMO) time is advantageous when treating delayed sleep-wake phase disorder (DSWPD) with low dose melatonin treatment plus behavioral interventions (i.e., evening dim light and time in bed (TIB) scheduling). METHODS: In this randomized, controlled, double-blind trial, 40 adults with DSWPD were randomly assigned to 4 weeks of 0.5 mg timed to be administered either 3 hours before the DLMO (measured DLMO group, n = 20) or 5 hours before sleep onset time per actigraphy (estimated DLMO group, n = 20), in conjunction with behavioral interventions...
March 6, 2024: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine